Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.
Primary Sponsor
ANZUP
Collaborating Groups
NHMRC CTC, TROG Cancer Research
Trial Chairperson
Prof Christopher Sweeney and Assoc/Prof Tamim Niazi
Trial Contact
dasl.study@sydney.edu.au
Related Post
October 18, 2022
NINJA Radiation Therapy Trial participant tells his journey to treatment
The journey to becoming the 200th participant for the
September 6, 2022
The gift that kept on giving
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
